CenterBook Partners’s Nektar Therapeutics NKTR Stock Holding History

CenterBook Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,407	Closed	-$533K	–	820
2026 Q1	$533K	Buy	+7,407	New	+$422K	0.03%	473

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CenterBook Partners's NKTR Position: Q2 2026 in Review

CenterBook Partners sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 7,407 shares — an estimated $533K sold.

CenterBook Partners first reported a position in NKTR in Q1 2026 and held it in 1 quarter. The position peaked at $533K in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

CenterBook Partners reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
CenterBook Partners sold 7,407 Nektar Therapeutics shares in Q2 2026, an estimated $533K.
CenterBook Partners first reported a position in Nektar Therapeutics in Q1 2026 and held it in 1 quarter.
CenterBook Partners's Nektar Therapeutics position peaked at $533K in Q1 2026.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.